We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Methods for Automated Anti-Neutrophil Cytoplasmic Antibodies Compared

By LabMedica International staff writers
Posted on 21 Oct 2020
Print article
Image: The EUROPattern Microscope Live: Ultrafast fluorescence microscopy that automatically detects anti-neutrophil cytoplasmic antibodies (Photo courtesy of EUROIMMUN AG).
Image: The EUROPattern Microscope Live: Ultrafast fluorescence microscopy that automatically detects anti-neutrophil cytoplasmic antibodies (Photo courtesy of EUROIMMUN AG).
The detection of anti-neutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence assays (IFA) is of diagnostic importance in vasculitis and some other inflammatory diseases.

Several laboratories use formaldehyde-fixed neutrophil granulocytes as an auxiliary substrate in addition to conventional ethanol fixation which is reported to be useful in differentiating between antinuclear antibody and ANCA and improves interpretation of patterns. Many, especially high throughput laboratories consider indirect immunofluorescence (IIF) methods cumbersome, labor intensive and time consuming.

A team of clinical scientists at the University of Debrecen (Debrecen, Hungary) collected serum samples from 570 individuals, whose referrals were suspicion of or follow-up for acute and chronic renal failure, ulcerative colitis, Crohn’s disease, systemic autoimmune diseases, vasculitis and autoimmune liver disorders. Five patients provided two samples.

Indirect immunofluorescence testing was performed using a reagent kit designed to be used with EUROPattern (EPa), EUROIMMUN’s computer-aided immunofluorescence microscope (Granulocyte Mosaic 13; EUROIMMUN AG, Lübeck, Germany). One reaction area on the microscope slide contains three biochips (2 x 2 mm, substrate coated cover slips), covered by ethanol- or formaldehyde-fixed human neutrophil granulocytes or granulocytes scattered on a HEp-2 cell layer, respectively. Fluorescein isothiocyanate labeled goat anti-human IgG was used as secondary antibody (conjugate), which was supplemented with Evans blue dye for red counterstaining of the cells.

Slides were processed manually and screening dilution of serum samples was 1:10. The automatic results and the digital images were presented to the user on a calibrated computer screen, who checked and validated the patterns. Finally, the slides were evaluated by means of traditional visual reading under an epifluorescence microscope (EUROStar II Plus, EUROIMMUN AG).

The team reported that agreement of discrimination between negative and non-negative samples was 86.1% comparing EPa and conventional reading, and it increased to 96.7% after on-screen user validation. Importantly, from the 334 samples classified as negative by EPa, 328 (98.2%) were also negative by conventional evaluation. Pattern recognition showed ‘moderate’ agreement between classical microscopic and EPa analysis and ‘very good’ agreement after user validation. Misclassification by EPa was dominantly due to the presence of anti-nuclear/cytoplasmic antibodies (incorrect pattern, 80/568) and the lower fluorescence cut-off of the automated microscope (false positives, 73/568).

The authors concluded that automated ANCA testing by EPa is a reliable alternative of classical microscopic evaluation, though classification of sera needs correction by trained personnel during on-screen validation. The study was published on September 28, 2020 in the journal Clinica Chimica Acta.



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.